Inactivated influenza vaccine adjuvanted with Bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion  by Keijzer, C. et al.
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Background:  Nasal  vaccination  is  considered  to  be a promising  alternative  for parenteral  vaccination
against  inﬂuenza  virus  as  it is non-invasive  and  offers  the  opportunity  to elicit  strong  antigen-speciﬁc
responses  both  systemic  and  locally  at the port  of entry  of  the  pathogen.  Previous  studies  showed  that
non-living  bacterium-like  particles  (BLPs)  from  the  food-grade  bacterium  Lactococcus  lactis  are  effective
stimulators  of local  and  systemic  immune  responses  when  administered  intranasally.  Moreover,  in  vitro,
BLPs  speciﬁcally  interact  with human  Toll-like  receptor  2 (TLR2),  suggestive  of  a role  for TLR2 dependent
immune  activation  by BLPs.
Methods: In the present  study,  we examined  the  role  of  TLR2  in  vivo in  immune  activation  after  nasal
administration  of  BLP  mixed  with  split  inﬂuenza  vaccine  (BLP-SV)  of inﬂuenza  A  virus  (IAV) using  TLR2
knockout  mice.
Results: The  systemic  Th1 cell and  subsequent  B-cell  responses  induced  after  intranasal  BLP-SV  vaccina-
tion  depended  on  the interaction  of  BLPs  with TLR2.  Notably,  the  BLP-SV-induced  class  switch  to  IgG2c
depended  on  the  interaction  of BLP  with  TLR2.  Local  induced  IAV-speciﬁc  Th1 cell  responses  and  the
mucosal  B-cell  responses  also depended  on interaction  of  BLP  with  TLR2.  Strongly  reduced  SIgA  levels
were  observed  in  TLR2  knockout  mice  both  in the  nasal  and  vaginal  lavages.  In addition,  detailed  analysis
of  the  T-cell  response  revealed  that nasal  BLP-SV  vaccination  promoted  Th1/Th17  immune  responses
that  coincided  with  increased  IAV-speciﬁc  IgG2c  antibody  production.
Discussion: Altogether  these  results  indicate  that  nasal  BLP-SV  vaccination  induces  IAV-speciﬁc  T-cell  and
B-cell  responses,  both  systemically  and at the  site  of  virus  entry  in a TLR2-dependent  manner.
©  2014 The  Authors.  Published  by Elsevier  Ltd.  Open access under CC BY-NC-ND license.. Introduction
Infection with inﬂuenza A virus (IAV) causes a contagious dis-
ase that affects mainly the upper respiratory tract and is still one
f the leading causes of mortality and morbidity worldwide [1,2].
ost vaccines against inﬂuenza A and B in use today are adminis-
ered via the parenteral route. Although these vaccines can induce
∗ Corresponding author at: Mucosis BV, L.J. Zielstraweg 1, NL-9713 GX Groningen,
he  Netherlands. Tel.: +31 50 8200053; fax: +31 50 8200051.
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ttp://dx.doi.org/10.1016/j.vaccine.2014.02.019
264-410X ©  2014  The  Authors.  Published  by  Elsevier  Ltd.  Open access under CC BY-NC-ND livirus-speciﬁc systemic immune responses, they barely activate the
mucosal immune system, the port of entry of the inﬂuenza viruses
[3,4]. Nasal vaccination therefore might be a promising alterna-
tive for parenteral vaccination against inﬂuenza virus, since this
route of vaccination resembles more closely natural infection and
it is known to elicit both systemic and mucosal immune responses
[4,5]. In addition, nasal vaccination might enhance vaccine efﬁ-
cacy in contrast to parenteral vaccination since nasal vaccination
is associated with secreted IgA (SIgA) antibody production at the
mucosal surfaces [5–7]. Because SIgA forms a ﬁrst line of defence
against invading pathogens at the portal of entry [8–10], it may
help to prevent penetration and replication of inﬂuenza virus in
the respiratory tract mucosa early after host cell invasion.
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The potential advantages of the nasal route of vaccination ren-
ers it attractive in the protection against respiratory infections,
owever, effective stimulation of the nasal mucosal immune sys-
em with non-replicating vaccine antigens usually requires the use
f an antigen carrier system and/or adjuvant [11,12]. However, this
oute of immunization is associated with the occurrence of facial
erve paralysis (Bell’s Palsy) as a result of the use of Escherichia coli
eat-labile toxin (LT) or mutants thereof, as adjuvant. Clearly, the
se of toxins or toxoids should be avoided as nasal adjuvant. An
xample of a recently developed nasal immunostimulatory system
s the bacterium-like particle (BLP) derived from the food-grade
acterium Lactococcus lactis [13,14]. BLPs are obtained by an acid
re-treatment, which degrades all cellular components, including
NA and proteins but leaves the peptidoglycan shell intact. The
esult is a non-living particle that still has the shape and size of
n untreated bacterium. The procedure is applicable to all Gram-
ositives, hence the name that was formerly used: Gram-positive
nhancer Matrix (GEM) [13,14]. Because of their safe use and adju-
ant activity [15,16], BLPs are an attractive adjuvant candidate for
he development of nasal inﬂuenza vaccines.
Previously, we showed that intranasal (i.n.) immunization
ith inﬂuenza monovalent subunit vaccine of strain A/Wisconsin
H3N2) mixed with BLPs strongly potentiate immunogenicity of
nﬂuenza subunit vaccine resulting in both local and systemic
mmune responses [15,16]. In vitro studies using a panel of
uman Toll-like receptors (TLRs) expressed in HEK293 cells sug-
est that BLPs have the capacity to mediate TLR2 signalling. Also,
LR2-speciﬁc blocking antibodies reduced the BLP-induced IL6
roduction by murine CD11c+ DCs in vitro [17]. However, it is
urrently unclear if TLR2 activation via BLPs is fully responsi-
le for the enhanced activation of the adaptive immune system
n vivo as measured by T-cell and B-cell activation. First of all,
LR2 can form heterodimers with other TLRs, speciﬁcally TLR1
nd TLR6 [18,19]. Especially TLR2/TLR1 heterodimers were shown
mportant in the induction of a protective mucosal Th17 immune
esponse in vivo, whereas TLR2/TLR6 heterodimers were not [20].
n addition, TLR2 is expressed on the surface of a large num-
er of immune cells including macrophages [21], monocytes and
endritic cells [22], M cells [23], B cells [24] and T cells [25] includ-
ng regulatory T cells [26] capable of differentially regulating the
mmune response. Although there is ample evidence that vaccina-
ion with BLP adjuvanted vaccines induces protective immunity, it
emains to be proven whether TLR2 mediated effects are respon-
ible for the observed activation of the adaptive immune response
n vivo.
To address the proposed role of TLR2 in vivo in the BLP-
ependent activation of the adaptive immune system, we explored
ocal and systemic inﬂuenza A virus speciﬁc T-cell and B-cell
esponses in TLR2 knockout (TLR2KO) and wild-type control mice
fter i.n. administration of BLPs supplemented with inactivated
nﬂuenza vaccine.
.  Materials and methods
.1.  Mice
Female BALB/c wild-type (wt) mice (6–8 weeks) were purchased
rom Harlan Laboratories, Zeist, The Netherlands. Six to eight weeks
ld C57BL6/J (wt) and B6.129-Tlr2tm1Kir/J mice (TLR2KO) were pur-
hased from Jackson Laboratories, France. All mice were kept under
tandard housing conditions at the University of Groningen, The
etherlands. Animal experiments were evaluated and approved
y the Committee for Animal Experimentation of the University of
roningen, The Netherlands, according to the guidelines provided
y Dutch Animal Protection Act. (2014) 2904–2910 2905
2.2.  Preparation of BLP-SV
Inﬂuenza  monovalent split vaccines of strain A/Beijing/262/95
(H1N1) and A/Sydney/5/97 (H3N2) were purchased from AdIm-
mune Corp, Taiwan (egg derived, formalin inactivated). The
concentration of the haemagglutinin (HA) in the vaccine was deter-
mined using the single radial immunodiffusion assay. The standard
BLP-SV vaccines consisted of inﬂuenza monovalent SV containing
5 g HA antigen mixed with BLPs (0.15 mg  dry-weight). BLPs were
prepared as described before [13,14]. BLPs were stored at −80 ◦C
until use. BLPs and SV, were mixed just prior to i.n. administration.
All i.n. vaccine doses were delivered in a ﬁnal volume of 10 l of
PBS.
2.3. Immunization
Mice to be i.n. immunized were lightly anaesthetized with
2.5%, v/v, isoﬂurane over oxygen (0.8 L/min). Once anaesthetized,
the mice were vaccinated i.n. every 10 days with 10 l of sterile
PBS containing BLP-SV (BLPs mixed with the inﬂuenza A strain
(A/Beijing/262/95 (H1N1)) or SV alone and sacriﬁced at day 34 of
the experiment. Mice were vaccinated i.n. 3 times on day 0, 14
and 28 with 10 l of sterile PBS containing BLP-SV (BLPs mixed
with the inﬂuenza A strain (A/Sydney/5/97(H3N2)) or SV alone
and sacriﬁced at day 42 of the experiment. SV without BLPs was
administered i.m. in 50 l of PBS as a positive control for the
immunogenicity of the antigenic materials.
2.4. Serum collection, nasal, lung and vaginal lavages
Blood was collected via puncture of the orbital plexus for
antibody measurements and the mice were sacriﬁced on day 34
or 42 via exsanguination by heart puncture under O2/isoﬂurane
anaesthesia. Subsequently, nasal, lung and vaginal washes were
conducted for SIgA antibody measurements. For nasal and lung
lavages, 1 ml  PBS that contained Roche “complete” protease
inhibitor (according to manufacturer’s description) was  used. The
tube containing the lavage ﬂuid was  placed on ice and centrifuged
at 300–400 × g for 5 min  at 4 ◦C and supernatants were collected.
Vaginal lavages were conducted by repeated pipetting of 0.2 ml  of
PBS supplemented with Roche “complete” protease inhibitor. All
lavage samples were stored at −20 ◦C.
2.5. IAV-speciﬁc IgG, IgG1, IgG2c and SIgA ELISA
ELISA was  performed as previously described [27]. Brieﬂy, ELISA
plates (Greiner, The Netherlands) were coated overnight at 4 ◦C
with inﬂuenza monovalent split vaccines of strain A/Sidney/5/97
H3N2 or A/Beijing/262/95 H1N1 (AdImmune). The plates were
washed twice and blocked in 200 l of a 2.5% solution of Protifar
Plus (NutriciaTM) in coating buffer (0.05 M carbonate-bicarbonate
pH  9.6–9.8) for 45 min  at 4 ◦C and washed four times before
samples were applied. Sera were applied in serial two-fold or
triple-fold dilutions and a mouse control serum sample positive
for A/Sidney/5/97 or A/Beijing/262/95 H1N1 was included on each
plate. For detection of SIgA, 100 l of the lavage was  used undi-
luted in the ﬁrst well and subsequently serial two-fold diluted. The
plates were incubated for 1.5 h at 4 ◦C, washed 3 times and incu-
bated for 1 h at 4 ◦C with anti-mouse Ig-HRP conjugates (Southern
Biotech). After incubation, the plates were washed 3–4 times and
incubated for 30 min  with 100 l staining solution (1 tablet of OPD
(o-Phenylenediamine dihydrochloride) dissolved in 100 ml  0.05 M
phosphate-citrate buffer pH 5.0 and 40 l H2O2). After incubation
the reaction was  stopped by adding 50 l 2 M H2SO4 per sample
and the absorbance was  determined at 492 nm.
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Fig. 1. Local and systemic T-cell and B-cell responses induced after i.n. BLP-SV vac-
cination are TLR2 dependent. C57BL6/J wt mice and TLR2KO mice were vaccinated
three  times with 10 l of BLP-SV (A/Sydney/5/97) or SV (A/Sydney/5/97) in PBS, i.n.
or i.m, respectively. Draining lymph nodes and spleens were isolated and single cells
were re-stimulated ex vivo with HA antigen for 48 h at 37 ◦C in anti-IFN- pre-coated
ELISPOT  plates for IAV-speciﬁc T-cell detection or directly cultured in Vaxigrip® pre-
coated plates to detect IAV-speciﬁc B-cells. Data are shown as the IAV-speciﬁc IFN-
T-cell count in dLN (A) and spleen (C) or as the IAV-speciﬁc B-cell count in dLN (B)
and spleen (D) per 106 cells above background (spots counted on medium coated
plates).  Data are shown as the mean ± SEM with n = 5 mice per group. Statistical906 C. Keijzer et al. / Vac
.6. IAV-speciﬁc IFN- T-cell and B-cell ELISPOT
The IAV-speciﬁc IFN- T-cell and IAV-speciﬁc B-cell response
n the spleen and local draining cervical lymph nodes (CLN) or
nguinal lymph nodes (ILN) after i.n. BLP-SV or i.m. SV vaccination,
espectively, was assessed by ELISPOT. For detection of IAV-speciﬁc
-cells, cells were directly cultured in high protein binding ﬁl-
er plates (MultiScreen-IP, Millipore) that were pre-coated with
axigrip® suspension for injection: strains 2009/2010, Sanoﬁ Pas-
eur MSD,  lot: E7068 at 1 g per well dissolved in 50 l of PBS.
or detection of IAV-speciﬁc IFN- T-cells, cells were cultured in
he presence of HA antigen or IMDM (Gibco, Invitrogen) medium
s a control that was supplemented with heat-inactivated 5% FCS
Bodinco, The Netherlands), 5 × 10−5 M 2-mercaptoethanol, peni-
illin (100 units/ml) and streptomycin (100 g/ml) (Gibco,
ermany) for 72 h at 37 ◦C in high protein binding ﬁlter plates
MultiScreen-IP, Millipore) that were pre-coated with a rat anti-
ouse IFN- monoclonal antibody (clone AN-18, purchased at BD
iosciences, Pharmingen) at 0.1 g per well dissolved in 50 l of
BS for 48 h at 37 ◦C.
After incubation, spot forming units of IAV-speciﬁc B- and T-
ells were detected with goat-anti-mouse IgG-biotin (Sigma) and
vidin-AP (Sigma). Plates were developed with NBT-BCIP (Roche)
nd analyzed by using the Aelvis spotreader and software. Data are
hown as IAV-speciﬁc IFN- T-cell or the IAV-speciﬁc B-cell count
er 106 cells above background.
.7.  Luminex
Single cell suspensions were prepared from spleen and drain-
ng lymph nodes and cells were cultured for 72 h in the presence
f ConA at 2.5 g/ml or IMDM (Gibco, Invitrogen) at 37 ◦C. Ana-
yzing the culture supernatants assessed the amount of cytokine
ecreted during a 72 h T-cell re-stimulation. Brieﬂy, ﬂuoresceinated
icrobeads coated with capture antibodies for simultaneous detec-
ion of IL-17A (TC11-18H10) and IL-5 (TRFK5) were added to 50 l
f culture supernatant. Cytokines were detected by biotinylated
ntibodies IL17 (DuoSet ELISA kit, R&D systems Europe Ltd, the
.K.), IL-5 (TRFK5) and PE-labelled streptavidin (BD Biosciences
harmingen). Fluorescence was measured using a Luminex model
00 XYP (Luminex, USA). Data are shown as the cytokine concen-
ration above background in pg/ml.
.8. Statistics
Statistical analysis was performed with Prism software (Graph-
ad Software Inc., San Diego, version 4.00). An unpaired two-tailed
-test was used in Fig. 2. One-way ANOVA followed by a Bonferroni’s
ultiple comparisons test was used in Fig. 4C. One-way ANOVA
ollowed by a Kruskal–Wallis test and Dunn’s multiple comparison
est was used in all other experiments.
. Results
To investigate the role of TLR2 in BLP-mediated local and sys-
emic IAV-speciﬁc T-cell and B-cell activation, B6.129-Tlr2tm1Kir/J
ice (TLR2KO) and C57BL6/J (wt controls) were immunized i.n.
ith BLP-SV (A/Sidney/5/97, H3N2). As a control, wt mice were i.m.
mmunized with SV alone. Fourteen days after the last immuniza-
ion, cells from the draining lymph nodes (dLN) and spleen were
solated and analyzed for IAV-speciﬁc IFN- producing cells and
AV-speciﬁc B-cells.In  the local dLN signiﬁcantly reduced numbers of IAV-speciﬁc
FN- producing T-cells (Fig. 1A) and lower numbers of IAV-speciﬁc
-cells (Fig. 1B) were observed in TLR2KO mice compared to the
umber of cells in wt control mice. Similar to the observationssigniﬁcance;  *P < 0.05.
made in the local dLN, also signiﬁcantly lower numbers of IAV-
speciﬁc IFN- producing T-cells (Fig. 1C) and a slight reduction in
IAV-speciﬁc B-cell numbers (Fig. 1D) were observed in the spleen
of TLR2KO mice compared to vaccinated wt mice. These data indi-
cate that induction of IAV-speciﬁc IFN- T-cell and B-cell responses
both in the local dLN and spleen requires interaction of BLP with
TLR2.
The IAV-speciﬁc IFN- T-cell responses in the dLN of wt con-
trols were slightly higher after i.n. BLP-SV immunization compared
to the responses after i.m. immunization with SV alone although
this did not reach statistical signiﬁcance. The systemic IFN- T-cell
response observed in spleen was similar after i.n. and i.m. immu-
nization (Fig. 1). Similar observations were made when BALB/c mice
were immunized i.n. and i.m. with BLP-SV and SV, respectively
(Table 1).
To  investigate how i.n. BLP-SV vaccination affects systemic T-
cell differentiation we analyzed IL-5 and IL-17A production of
activated splenocytes. After i.n. BLP-SV vaccination the enhanced
IAV-speciﬁc IFN- T-cell responses coincided with a slightly
increased production of IL-17A cytokine (Fig. 2A) and signiﬁ-
cantly decreased secretion of IL-5 cytokine (Fig. 2B) compared
to SV i.m. vaccinated mice. Together these results indicate that
the IAV-speciﬁc T-cell and B-cell responses induced after i.n. BLP-
SV administration are TLR2 dependent and results in Th1/Th17
skewing.
C. Keijzer et al. / Vaccine 32 (2014) 2904–2910 2907
Table  1
Local  and systemic T-cell responses induced after vaccination in BALB/c mice.
Vaccine formulation Route of administration IFN- producing cells (per 106 cells)
Spleen dLN
BLP-SV Intranasal 93 ± 12 70 ± 30
SV  Intramuscular 114 ± 30 20 ± 10
BALB/c mice were vaccinated three times with 10 l of BLP-SV (A/Beijing/262/95) or SV 
and single cells were re-stimulated ex vivo with HA antigen for 48 h at 37 ◦C in anti-IFN-
IAV-speciﬁc IFN- T-cell count per 106 cells above background (spots counted on medium
Fig. 2. Intranasal BLP-SV vaccination results in Th1/Th17 skewing. C57BL6/J wt
mice were vaccinated three times with 10 l of BLP-SV (A/Sydney/5/97) or SV
(A/Sydney/5/97)  in PBS i.n. or i.m, respectively. Spleens were isolated and single
cells  were re-stimulated ex vivo with ConA for 72 h at 37 ◦C. Cytokine concentra-
tions  in pg/ml of IL-17A (A) and IL-5 (B) were determined in culture supernatants.
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were found to protect mice against lethal inﬂuenza pneumoniaata  are shown as the mean ± SEM with n = 5 mice per group. Statistical signiﬁcance;
P<  0.05.
Activation of B-cells in mucosa-associated lymphoid tissues is
ssociated with production of SIgA at the mucosal surfaces [8,9].
o investigate whether the reduced IAV-speciﬁc B-cells in the dLN
n TLR2KO mice affect the production of SIgA, nasal and peripheral
aginal lavages were analyzed for SIgA antibodies. In wt mice sig-
iﬁcant levels of SIgA were observed locally in the nasal and lung
avages, but also in the peripheral vaginal lavages after i.n. BLP-SV
dministration, while mice vaccinated i.m. with SV alone showed
ecreased or absent SIgA levels (Fig. 3A). In contrast to the levels
bserved in wt mice, low to absent SIgA levels were measured in
asal (Fig. 3B) and vaginal (Fig. 3C) lavages in TLR2KO mice. In addi-
ion, very low levels of SIgA antibodies were measured in mucosal
avages when SV alone was administered either i.n. or i.m. The data
how that local and peripheral SIgA production after i.n. BLP-SV
dministration depends on the interaction of BLP with TLR2.
Next,  we explored if the observed enhanced IAV-speciﬁc B-
ell response after i.n. BLP-SV vaccination in wt  mice compared to
LR2KO mice as shown in Fig. 1 also affected IAV-speciﬁc systemic
ntibody production.
We  observed an enhanced IAV-speciﬁc IgG response in serum
f wt mice after booster vaccination with i.n. BLP-SV in contrast
o vaccinated TLR2KO mice, which resembles the IgG response of
he SV vaccine in wt mice (Fig. 4A and B). Then, we investigated
f IgG class switch to IgG1 or IgG2c after i.n. BLP-SV vaccination
lso depended on TLR2 interaction. Here, we showed that the BLP-
V-induced class switch to IgG2c depended on the interaction of
LP with TLR2 (Fig. 4C). In contrast, the IAV-speciﬁc IgG1 response
as not reduced in TLR2KO mice compared to wt  control miceFig. 4D). We  therefore suggest that the increase in IgG1 in the
LR2KO mice after both i.n. BLP-SV and SV immunization might
ndicate an inhibitory role for TLR2 on class switch to IgG1.(A/Beijing/262/95) in PBS, i.n. or i.m, respectively. dLNs and spleens were isolated
 pre-coated ELISPOT plates for IAV-speciﬁc T-cell detection. Data are shown as the
 coated plates). Data are shown as the mean ± SEM with n = 5 mice per group.
Thus, both IAV-speciﬁc systemic Th1 cell and subsequent B-
cell responses that were associated with enhanced IgG2c antibody
production induced after i.n. BLP-SV vaccination depended on
interaction of BLP with TLR2.
4. Discussion
Earlier studies have demonstrated in vitro that BLPs can acti-
vate TLR2 signalling in human TLR-transfected HEK  cells and mouse
dendritic cells [17]. This implies that TLR2 activation by BLP could
be responsible for enhancing adaptive immune responses in vivo,
but formal proof for this was lacking. Previous studies showed
that the effect of TLR2 triggering on the outcome of the immune
response in vivo is variable and depends on several unknown fac-
tors: TLR2 can form heterodimers with other TLRs, speciﬁcally TLR1
and TLR6 [18,19] and TLR2 is expressed by a plethora of immune
cells [21–26]. Furthermore, the immunostimulatory activity of BLPs
in vivo could be the result of activation of innate receptors different
from TLR, for example, NOD receptors. Here, we provided clear evi-
dence for an essential role of TLR2 in the BLP-dependent activation
of the IAV-speciﬁc adaptive immune responses in vivo upon nasal
vaccination.
Moreover, we  showed that both local and systemic IAV-speciﬁc
IFN- T-cell (Fig. 1A and C) and B-cell responses (Fig. 1B and 1D)
required the activation of TLR2 by BLPs given that the number of
cells was  substantially reduced in TLR2KO mice after i.n. BLP-SV
vaccination compared to wt control mice. Since IFN- producing
Th1 cells are known to promote IgG2c production by B-cells [28], we
explored if the IgG class switch to IgG2c also depended on the inter-
action of BLPs with TLR2. The data showed a signiﬁcantly reduced
IAV-speciﬁc IgG2c antibody production in TLR2KO mice after i.n.
BLP-SV vaccination compared to wt  control mice (Fig. 4C) that
correlated with reduced numbers of IFN- producing T-cells. There-
fore, we  suggest that the enhanced IgG class switch to IgG2c was
mediated by IAV-speciﬁc IFN- producing T-cells and this required
the interaction of BLPs with TLR2. Since interaction of BLPs with
TLR2 skewed the responses towards Th1 type, i.n. BLP-SV vaccina-
tion, as expected, did not affect IgG class switch to IgG1 (Fig. 4D).
In addition, we  found that i.n. BLP-SV vaccination also modestly
enhanced the response towards Th17 type (Fig. 2A). The role of
Th17 and other IL-17 producing cells in protection against inﬂuenza
infections is still not completely clear [29]. However, IL-17 produc-
ing cells might be beneﬁcial in protection against severe inﬂuenza
infections, since enhanced numbers of IL-17 producing inﬂuenza
speciﬁc T cells can protect the host against an, otherwise lethal,
inﬂuenza infection [30]. Surprisingly, the inﬂuenza A virus itself
has been described to inhibit Th17-mediated immunity thereby
enhancing the risk of complicating secondary Staphylococcus aureus
infections [31].
TLR  ligands have been studied previously in inﬂuenza virus stud-
ies and i.n. pre-treatments with especially TLR2 and TLR4 ligandsin an antigen independent manner [32]. Moreover, i.n. immuniza-
tion with inﬂuenza-derived peptides coupled to bacterial-derived
lipids induced DC maturation via TLR2 binding and enhanced
2908 C. Keijzer et al. / Vaccine 32 (2014) 2904–2910
Fig. 3. Local and peripheral IAV-speciﬁc SIgA responses induced after i.n. BLP-SV vaccination are TLR2 dependent. BALB/c wt mice were vaccinated three times with 10 l
of  BLP-SV (A/Beijing/262/95) or SV (A/Beijing/262/95) in PBS, i.n. or i.m, respectively. Nasal, lung and vaginal lavages were collected and IAV-speciﬁc SIgA production was
detected  with ELISA (A). C57BL6/J wt mice and TLR2KO mice were vaccinated three times i.n. with 10 l of BLP-SV (A/Sydney/5/97) or SV (A/Sydney/5/97) in PBS. For the
detection of IAV-speciﬁc SIgA titres, nasal (B) and vaginal (C) lavages were collected and IAV-speciﬁc SIgA antibody production was detected with ELISA. Data are shown as
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ctivation of IFN- secreting CD8+ T-cells at the site of infection
fter i.n. exposure to inﬂuenza virus [33]. Earlier it was shown that
asal immunization with BLP activated and enhanced the matura-
ion of dendritic cells (DCs) that enhanced the activation of IFN-
roducing CD4+ T-cells [17]. However, the BLP interaction with
LR2 in vivo might involve other cell types since TLR2 is expressed
n many immune cells, including B-cells [24]. For example, B-
ell intrinsic MyD88 signals can also drive IFN- production from
-cells and result in enhanced T-cell dependent IgG2c antibody
esponses [34]. Therefore, we suggest that the interaction of BLPs
ith TLR2 expressed by antigen presenting cells, such as dendritic
ells but also B cells, requires further investigation to understand
he mechanism that drives the immunological outcome after nasal
accination.
SIgA at mucosal tissues forms a ﬁrst line of defence against
nvading pathogens at the port of entry [8–10], therefore, we
xplored if the induction of mucosal SIgA responses after i.n. BLP-
V vaccination required BLP interaction with TLR2. Indeed, the data
howed that SIgA responses measured in nasal (Fig. 3B) and vaginal
avages (Fig. 3C) were TLR2 dependent. Previously, it was shown
hat i.n. vaccination with BLP vaccines induced enhanced SIgA at
ucosal tissue in BALB/c mice compared to parenteral vaccination
15,35]. The potency to induce a mucosal SIgA response was inde-
endent of the mouse strain tested, as both C57BL6/J and BALB/c
ice induced strong responses (Fig. 3). Similar to the local immunereatment and ﬁgures (B) and (C) with n = 10 mice per group. Statistical signiﬁcance;
response  induced by BLP adjuvanted vaccination, also systemically
induced immune responses in BALB/c and C57BL6/J are comparable
as shown by enhanced IFN- producing cells and IAV-speciﬁc IgG
titres [17,35].
Although the IL-5 cytokine is a differentiation marker for B-
cells that produce IgA [36] we did not detect signiﬁcant IL-5
cytokine secretion after i.n. BLP-SV vaccination (Fig. 2B). Since TLR2
signalling can also trigger IgA production by human B-cells directly
[37], we  suggest that the SIgA responses are at least partly enhanced
due to the interaction of BLP with TLR2 on B cells (Fig. 3B and C).
Previously,  it has been shown that BLP adjuvanted vaccines
induce protective immunity to subsequent infection [15,17]. More-
over, recent data showed that i.n. vaccination with a BLP adjuvanted
inﬂuenza vaccine results in improved protection against both
homologous and heterologous inﬂuenza challenge infections as
compared to protection levels observed after conventional par-
enteral inﬂuenza vaccination [35]. These data underline that
enhanced systemic and mucosal B-cell responses induced by i.n.
vaccination with BLPs result in a strong protective and broad
immune response.
In  conclusion, the interaction of BLPs with TLR2 in vivo is
required for the enhanced activation of systemic and local IAV-
speciﬁc adaptive immune responses as observed after i.n. BLP-SV
vaccination. Especially the ability to induce local IAV-speciﬁc
immune responses, in particular elevated levels of IAV-speciﬁc
C. Keijzer et al. / Vaccine 32 (2014) 2904–2910 2909
Fig. 4. Intranasal BLP-SV vaccination induced B-cell responses result in TLR2 dependent IgG2c antibody production. C57BL6/J wt  mice and TLR2 KO mice were vaccinated
three times i.n. with 10 l of BLP-SV (A/Sydney/5/97) or SV (A/Sydney/5/97) in PBS. For IAV-speciﬁc IgG responses, serum was collected and IAV-speciﬁc IgG production was
detected with ELISA. Data are shown as IAV-speciﬁc IgG titres in serum after a priming, booster and second booster vaccination (A). Data are shown as the IAV-speciﬁc IgG
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[itre  after the second booster vaccination (B). For IgG class switch, serum was  collec
D)  responses were detected with ELISA. Data are shown as the mean ± SEM with n
FN- producing T-cells and IgA antibody secreting B-cells,
ake BLPs an attractive immune stimulator to be used in nasal
accination against inﬂuenza infection.
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